Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Aim: Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). Patients & metho...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Taylor & Francis Group 2019-06-01
Reeks:	CNS Oncology
Onderwerpen:	bevacizumab glioblastoma glioma long term progression recurrence
Online toegang:	https://www.futuremedicine.com/doi/10.2217/cns-2019-0007

Gelijkaardige items

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
door: Alissa Thomas, et al.
Gepubliceerd in: (2018-01-01)

A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab
door: Josie Hayes, et al.
Gepubliceerd in: (2016-10-01)

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
door: Patrick Roth, et al.
Gepubliceerd in: (2020-06-01)

Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study
door: Bai X, et al.
Gepubliceerd in: (2024-11-01)

Bevacizumab in recurrent WHO grades II–III glioma
door: Soufyan Annakib, et al.
Gepubliceerd in: (2023-07-01)

Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab
door: Joan Manel Gasent Blesa, et al.
Gepubliceerd in: (2012-12-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
door: D. R. Naskhletashvili, et al.
Gepubliceerd in: (2015-04-01)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
door: Mesti Tanja, et al.
Gepubliceerd in: (2015-03-01)

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
door: Moire Cuncannon, et al.
Gepubliceerd in: (2019-05-01)

The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials
door: SiYao Wei, et al.
Gepubliceerd in: (2024-07-01)

Mechanism and significance of diffusion restriction followed by calcification in high-grade glioma treated with bevacizumab
door: Tomohiro Hosoya, et al.
Gepubliceerd in: (2024-11-01)

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells
door: Mesti Tanja, et al.
Gepubliceerd in: (2018-11-01)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
door: N. García-Romero, et al.
Gepubliceerd in: (2020-06-01)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
door: Masahiro Nishikawa, et al.
Gepubliceerd in: (2021-03-01)

Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis
door: Zhaoyan Chen, et al.
Gepubliceerd in: (2024-05-01)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
door: Kathleen Van Dyk, et al.
Gepubliceerd in: (2022-06-01)

Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
door: Amy eBarone, et al.
Gepubliceerd in: (2013-04-01)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
door: Hiroyuki Tatekawa, et al.
Gepubliceerd in: (2021-03-01)

Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma
door: Rebecca Kassubek, et al.
Gepubliceerd in: (2023-05-01)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
door: Celina Bihan, et al.
Gepubliceerd in: (2012-09-01)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
door: Eudocia Q. Lee, et al.
Gepubliceerd in: (2019-10-01)

Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center
door: Margarida Simão-Rafael, et al.
Gepubliceerd in: (2023-12-01)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
door: Pia Banerjee, et al.
Gepubliceerd in: (2015-01-01)

Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
door: Ramon F. Barajas, et al.
Gepubliceerd in: (2016-10-01)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
door: George Ansstas, et al.
Gepubliceerd in: (2016-01-01)

Differential expression of the circadian clock network correlates with tumour progression in gliomas
door: Marina Petkovic, et al.
Gepubliceerd in: (2023-07-01)

Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
door: Barbara Castelli, et al.
Gepubliceerd in: (2023-09-01)

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
door: Giovanni Luca Gravina, et al.
Gepubliceerd in: (2017-01-01)

Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis
door: Dong Liu, et al.
Gepubliceerd in: (2024-07-01)

Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
door: Barbara Castelli, et al.
Gepubliceerd in: (2024-02-01)

Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab
door: Samy Ammari, et al.
Gepubliceerd in: (2021-07-01)

Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review
door: Oguz Ozel, et al.
Gepubliceerd in: (2016-08-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
door: Emil Lou, et al.
Gepubliceerd in: (2013-04-01)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
door: Seung Won Choi, et al.
Gepubliceerd in: (2018-05-01)

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
door: Minjie Fu, et al.
Gepubliceerd in: (2023-06-01)

Circadian Alterations in a Murine Model of Hypothalamic Glioma
door: José M. Duhart, et al.
Gepubliceerd in: (2017-10-01)

Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines
door: Valerie J. Marallano, et al.
Gepubliceerd in: (2024-03-01)

Selected cytostatic drugs in the treatment of brain glioma – literature review
door: Jarosław Bała, et al.
Gepubliceerd in: (2021-11-01)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
door: Lei She, et al.
Gepubliceerd in: (2022-08-01)

A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy
door: Shanmu Jin, et al.
Gepubliceerd in: (2024-03-01)